About Novartis Pharmaceuticals Australia Pty Ltd
Novartis Pharmaceuticals Australia Pty Ltd: A Global Healthcare Company
Novartis Pharmaceuticals Australia Pty Ltd is a subsidiary of Novartis, a global healthcare company based in Switzerland. The company provides innovative solutions to address the evolving needs of patients worldwide. With a strong focus on research and development, Novartis has become one of the leading pharmaceutical companies in the world.
History
Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two Swiss pharmaceutical companies with long histories dating back to the 19th century. Since then, Novartis has grown into a multinational corporation with operations in more than 140 countries.
Products and Services
Novartis offers a wide range of products and services across several therapeutic areas, including oncology, cardiology, respiratory diseases, neuroscience, ophthalmology, immunology and dermatology. Some of its most well-known brands include Gilenya for multiple sclerosis; Lucentis for age-related macular degeneration; Tasigna for chronic myeloid leukemia; Cosentyx for psoriasis; Entresto for heart failure; and Zolgensma for spinal muscular atrophy.
Research & Development
Research & Development (R&D) is at the core of Novartis' business strategy. The company invests heavily in R&D to discover new treatments that can improve patient outcomes. In 2020 alone, Novartis invested USD 9.9 billion in R&D activities globally.
Innovation
Innovation is another key aspect of Novartis' business strategy. The company aims to develop innovative solutions that can address unmet medical needs or improve existing treatments. For example:
- In oncology: Novartis developed Kymriah®, a CAR-T cell therapy that reprograms patients' own immune cells to fight cancer.
- In ophthalmology: Lucentis® was one of the first drugs approved by regulatory authorities to treat wet age-related macular degeneration (AMD).
- In neuroscience: Mayzent® was approved as an oral treatment option for secondary progressive multiple sclerosis (SPMS).
Corporate Social Responsibility
As a global healthcare company with significant influence on public health outcomes worldwide, Novartis takes its corporate social responsibility seriously. The company's CSR initiatives focus on three main areas:
1) Expanding access to healthcare
2) Environmental sustainability
3) Ethical business practices
Expanding Access To Healthcare:
One way that Novaris expands access to healthcare is through its partnership with governments around the world who are working towards universal health coverage goals by providing affordable medicines.
Environmental Sustainability:
The second area where they focus their CSR efforts is environmental sustainability which includes reducing greenhouse gas emissions from their operations as well as reducing waste generation.
Ethical Business Practices:
Finally ethical business practices are also important part where they ensure compliance with all applicable laws regulations while conducting their businesses ethically.
Conclusion:
In conclusion we can say that "Novaris Pharmaceuticals Australia Pty Ltd" being part of such an esteemed organization like "Novaris" has been able provide innovative solutions across various therapeutic areas which have helped millions around globe live better lives . Their commitment towards research & development , innovation , corporate social responsibility makes them stand out among other pharmaceutical companies globally .
novartis.com.au
